Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CHFR divergent transcript (CHFR-DT) is a long non-coding RNA transcribed from the promoter region of the CHFR gene in the antisense direction. Divergent transcription, which gives rise to such non-coding RNAs, is a widespread phenomenon in mammalian genomes and is associated with promoters of genes involved in transcriptional regulation and development. These transcripts typically have low or no protein-coding potential and may contribute to local chromatin structure or fine-tuning of gene expression, although their specific biological roles—especially for CHFR-DT—are poorly understood. There is no evidence that CHFR-DT has direct clinical or pathological significance, nor is it currently a therapeutic target.
None known/applicable for drug targeting—no drugs known to act on CHFR-DT.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CHFR divergent transcript (CHFR-DT).